| Original language | English (US) |
|---|---|
| Pages (from-to) | 1163-1164 |
| Number of pages | 2 |
| Journal | JAMA Cardiology |
| Volume | 5 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2020 |
| Externally published | Yes |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: JAMA Cardiology, Vol. 5, No. 10, 10.2020, p. 1163-1164.
Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - Heroism in the Face of the COVID-19 Pandemic
AU - Bonow, Robert O.
AU - Kirtane, Ajay J.
AU - Mehran, Roxana
AU - Navar, Ann Marie
AU - Bonow, Robert O.
N1 - Funding Information: reported receiving institutional funding to Columbia University and/or the Cardiovascular Research Foundation for research, speaking engagements, and/or consulting from Medtronic plc, Boston Scientific Corporation, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens AG, Philips, and ReCor Medical; and travel expenses/meals from Medtronic plc, Boston Scientific Corporation, Funding Information: Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, ReCor Medical, Chiesi USA, OpSens, Inc, ZOLL, and Regeneron Pharmaceuticals, Inc. Dr Mehran reported receiving grants and/or research institutional funding from AstraZeneca plc, Medtronic plc, Janssen Pharmaceutica, Bayer AG, Beth Israel Deaconess, CSL Behring, DSI, Novartis International AG, OrbusNeich, Novartis Pharmaceuticals, Sanofi/ Regeneron, and Boston Scientific Corporation; personal fees from Sanofi SA, Medscape/WebMD, Roivant Services, Siemens Medical Solutions, Boston Scientific Corporation, Janssen Scientific Affairs, and Medtelligence (Janssen Scientific Affairs); grants, personal fees, and other support from Abbott Laboratories; grants and other support from Bristol-Myers Squibb; personal fees to her spouse from Abiomed and The Medicines Company; consulting relationships with Idorsia Pharmaceuticals Ltd, Regeneron Pharmaceuticals, Inc, and Spectranetics/Philips/Volcano Corp; participation in a data safety and monitoring board for Watermark Research Partners; service as an associate editor to the American College of Cardiology and the American Medical Association; and equity in Claret Medical and Elixir Medical Corporation outside of the submitted work. Dr Navar reported receiving funding for research to her institution from Amgen, Inc, Janssen Pharmaceutica, Amarin Corporation, Sanofi SA, and Regeneron Pharmaceuticals, Inc, and honoraria and consulting fees from Amgen, Inc, AstraZeneca plc, Janssen Pharmaceutica, Esperion Therapeutics, Inc, Amarin Corporation, Sanofi SA, Regeneron Pharmaceuticals, Inc, Novo Nordisk A/S, Novartis Pharmaceuticals, The Medicines Company, New Amsterdam, Cerner Corporation, 89bio, Inc, and Pfizer, Inc.
PY - 2020/10
Y1 - 2020/10
UR - http://www.scopus.com/inward/record.url?scp=85086716449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086716449&partnerID=8YFLogxK
U2 - 10.1001/jamacardio.2020.2493
DO - 10.1001/jamacardio.2020.2493
M3 - Editorial
C2 - 32558909
AN - SCOPUS:85086716449
SN - 2380-6583
VL - 5
SP - 1163
EP - 1164
JO - JAMA Cardiology
JF - JAMA Cardiology
IS - 10
ER -